Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. - Arnold DL; Sprenger T; Bar-Or A; Wolinsky JS; Kappos L; Kolind S; Bonati U; Magon S; van Beek J; Koendgen H; Bortolami O; Bernasconi C; et al. (Multiple sclerosis (Houndmills, Basingstoke, England), 2022)